SEARCH

SEARCH BY CITATION

References

  • 1
    Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97:596601.
  • 2
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:15951607.
  • 3
    Grundy SM, Brewer HB, Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433438.
  • 4
    Donati MB. The “common soil hypothesis”: evidence from population studies? Thromb Res. 2010;125(suppl 2):S92S95.
  • 5
    Reaven GM. The metabolic syndrome: time to get off the merry-go-round? J Intern Med. 2011;269:127136.
  • 6
    Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:16401645.
  • 7
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:27352752.
  • 8
    National Cholesterol Education Program (NCEP). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:31433421.
  • 9
    Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416422.
  • 10
    Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:11911201.
  • 11
    Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones – what do meta-analyses really tell us? Diabetes Obes Metab. 2010;12:10231035.
  • 12
    Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309.
  • 13
    Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385411.
  • 14
    Diabetes Prevention Program Research Group; Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:16771686.
  • 15
    Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010;375:181183.
  • 16
    Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28:19161921.
  • 17
    Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:30463051.
  • 18
    Manttari M, Huttunen JK, Koskinen P, et al. Lipoproteins and coronary heart disease in the Helsinki Heart Study. Eur Heart J. 1990;11(suppl H):2631.
  • 19
    Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:18491861.
  • 20
    Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358:21302131.
  • 21
    Gupta A, Gupta R, Sarna M, et al. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract. 2003;61:6976.
  • 22
    Ramachandran A, Snehalatha C, Satyavani K, et al. Metabolic syndrome in urban Asian Indian adults – a population study using modified ATP III criteria. Diabetes Res Clin Pract. 2003;60:199204.
  • 23
    Misra A, Vikram NK. Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition. 2004;20:482491.
  • 24
    Vikram NK, Pandey RM, Misra A, et al. Non-obese (body mass index < 25 kg/m2) Asian Indians with normal waist circumference have high cardiovascular risk. Nutrition. 2003;19:503509.
  • 25
    Misra A. Revisions of cutoffs of body mass index to define overweight and obesity are needed for the Asian-ethnic groups. Int J Obes Relat Metab Disord. 2003;27:12941296.
  • 26
    Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93(suppl 1):S9S30.
  • 27
    Misra A, Chowbey P, Makkar BM, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163170.
  • 28
    Chiu KC, Chuang LM, Yoon C, Saad MF. Hepatic glucokinase promoter polymorphism is associated with hepatic insulin resistance in Asian Indians. BMC Genet. 2000;1:2.
  • 29
    Abate N, Carulli L, Cabo-Chan A Jr, et al. Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. J Clin Endocrinol Metab. 2003;88:59275934.
  • 30
    Miller M, Rhyne J, Chen H, et al. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res. 2007;38:444451.
  • 31
    Joseph A, Kutty VR, Soman CR. High risk for coronary heart disease in Thiruvananthapuram city: a study of serum lipids and other risk factors. Indian Heart J. 2000;52:2935.
  • 32
    Bhalodkar NC, Blum S, Enas EA. Accuracy of the ratio of triglycerides to high-density lipoprotein cholesterol for predicting low-density lipoprotein cholesterol particle sizes, phenotype B, and particle concentrations among Asian Indians. Am J Cardiol. 2006;97:10071009.
  • 33
    Enas EA, Garg A, Davidson MA, et al. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J. 1996;48:343353.
  • 34
    Cromwell WC. High-density lipoprotein associations with coronary heart disease: does measurement of cholesterol content give the best result? J Clin Lipidol. 2007;1:5764.
  • 35
    Bhalodkar NC, Blum S, Rana T, et al. Comparison of levels of large and small high-density lipoprotein cholesterol in Asian Indian men compared with Caucasian men in the Framingham Offspring Study. Am J Cardiol. 2004;94:15611563.
  • 36
    Scanu AM. Lp(a) lipoprotein – coping with heterogeneity. N Engl J Med. 2003;349:20892090.
  • 37
    Enas EA, Chacko V, Senthilkumar A, et al. Elevated lipoprotein(a) – a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. Dis Mon. 2006;52:550.
  • 38
    Gupta R. Meta-analysis of prevalence of hypertension in India. Indian Heart J. 1997;49:4348.
  • 39
    Mohan B, Kumar N, Aslam N, et al. Prevalence of sustained hypertension and obesity in urban and rural school going children in Ludhiana. Indian Heart J. 2004;56:310314.
  • 40
    King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:14141431.
  • 41
    Radhika G, Sathya RM, Sudha V, et al. Dietary salt intake and hypertension in an urban south Indian population – [CURES – 53]. J Assoc Physicians India. 2007;55:405411.
  • 42
    Bhopal RS. Heterogeneity among Indians, Pakistanis, and Bangladeshis is key to racial inequities. BMJ. 2002;325:903.
  • 43
    Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord. 2009;7:497514.